Video Experimental Relacionado
Updated: Feb 28, 2026
10:50
Molecular Modulation by Lentivirus-Delivered Specific shRNAs in Endoplasmic Reticulum Stressed Neurons
Published on: April 24, 2021
1.4K
Inhibición Farmacológica de SLC33A1 Promueve la Hiperoxidación del Retículo Endoplasmático e Induce la Señalización
bioRxiv : the preprint server for biology
|February 27, 2026
Resumen
La molécula pequeña IXA4 inhibe el transportador ER SLC33A1, afectando la homeostasis redox del ER. Este descubrimiento ofrece una nueva estrategia terapéutica para enfermedades como el cáncer de pulmón al dirigirse a SLC33A1.
Área de la Ciencia:
- Bioquímica
- Biología Molecular
- Biología Celular
Sus antecedentes:
- El transportador del retículo endoplasmático (RE) SLC33A1 es una diana terapéutica potencial para diversas enfermedades.
- Actualmente, no existen moduladores farmacológicos específicos para SLC33A1.
Objetivo del estudio:
- Identificar y caracterizar moduladores farmacológicos de SLC33A1.
- Investigar el papel de SLC33A1 en la señalización celular y la homeostasis.
- Explorar el potencial terapéutico de la inhibición de SLC33A1.
Principales métodos:
- Cribado y caracterización de moléculas pequeñas (IXA4).
- Manipulación genética (depleción de SLC33A1).
- Análisis quimioproteómico y crio-microscopía electrónica.
- Ensayos de viabilidad celular.
Principales resultados:
- IXA4 se une selectivamente e inhibe la actividad de SLC33A1.
- La inhibición de SLC33A1 conduce a la hiperoxidación del lumen del RE y a la activación de la señalización IRE1/XBP1s.
- El tratamiento con IXA4 reduce selectivamente la viabilidad en células de adenocarcinoma de pulmón deficientes en KEAP1.
- La depleción genética de SLC33A1 fenocopia los efectos de IXA4.
Conclusiones:
- SLC33A1 desempeña un papel crucial en la regulación de la homeostasis redox del RE.
- IXA4 es un inhibidor farmacológico novedoso de SLC33A1.
- La inhibición de SLC33A1 con IXA4 presenta una vía terapéutica potencial para cánceres específicos y otras enfermedades.
Videos de Conceptos Relacionados
01:31Regulation of the Unfolded Protein Response
3.1K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
3.1K
01:37The Unfolded Protein Response
6.6K
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
6.6K
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
77
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
77
01:32Export of Misfolded Proteins out of the ER
5.4K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
5.4K
01:45ER Retrieval Pathway
4.9K
In the secretory pathway, vesicles transport proteins from one cellular compartment to another in forward transport to deliver the protein to its correct location. Occasionally, misfolded proteins and incorrect proteins escape their original compartments, and a retrieval pathway is used to return the escaped proteins to their original compartment.
The ER uses many checkpoints to prevent the entry of incorrectly folded or a resident protein as cargo onto a transport vesicle. These mechanisms...
The ER uses many checkpoints to prevent the entry of incorrectly folded or a resident protein as cargo onto a transport vesicle. These mechanisms...
4.9K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
54
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
54